Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01905423
Other study ID # 201103313
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2011
Est. completion date December 2015

Study information

Verified date October 2020
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W. bancrofti endemic areas over a period of 4 years. Participants will be studied only once in cross-sectional surveys. Some subjects may be included in more than one annual population survey, but this is not a longitudinal study. Purpose of the study is to evaluate different mass drug administration (MDA) regimens for lymphatic filariasis and also to study the impact of MDA on soil transmitted helminth infections (STH). MDA will administered by others (e.g., Ministry of Health). Results of this study may enhance efforts to control and eliminate these important neglected tropical diseases. The investigators will test the hypothesis that accelerated mass drug administration will be superior to annual MDA for elimination of lymphatic filariasis and for control of soil transmitted helminth infections (STH): 1. Compare the relative impact and cost effectiveness of annual vs. twice yearly mass drug administration (MDA) for elimination of lymphatic filariasis (LF). 2. Study the impact of annual vs. semiannual MDA on soil transmitted helminth (STH) infection in these populations.


Description:

Lymphatic filariasis (LF) is a deforming and disabling infectious disease that causes elephantiasis and genital deformity (especially hydroceles). The infection affects some 120 million people in 81 countries in tropical and subtropical regions with well over 1 billion people at risk of acquiring the disease. LF is caused by Wuchereria bancrofti and Brugia spp. (B. malayi and B.timori), nematode parasites that are transmitted by mosquitoes. This study is based on the assumption that currently used mass drug administration (MDA) regimens and schedules are not optimal for achieving elimination of LF. These regimens (either annual Albendazole (Alb) 400 mg plus diethylcarbamazine (DEC) 6 mg/kg or Alb 400 mg plus ivermectin (Iver) 200 µg/kg for LF) were developed more than 10 years ago. Drugs used for LF MDA are also active against soil transmitted helminth infections (STH, e.g., Ascaris, Hookworm, and Trichuris). De-worming campaigns using anthelminthics usually target special groups of the population, such as schoolchildren, and have limited impact on the transmission. Treatment of the total population and semiannual treatments may reduce re-infection considerably and will most likely lead to reduced infection densities and infection prevalences. Suppression of STH is an important ancillary benefit of MDA programs for filarial infections. Purpose: The study aims to compare the effectiveness once yearly (1X) versus twice yearly (2X) mass drug administration (MDA) for the elimination of lymphatic filariasis and for control of soil-transmitted helminths (intestinal parasites) in large populations. Mass drug administration will be provided by the Indonesia Ministry of Health. This project will assess the impact of the public health program. Procedures: Study procedures include collection of finger prick blood that will be tested for microfilaremia and for serology testing (antigenemia and antibody testing). Stool samples will be collected to detect STH infections. All assays will be performed in Indonesia (filarial serology tests, blood smears for detection of microfilariae (MF), and stool examinations for detection of worm eggs). Washington University researchers developed the protocol, will provide training and guidance to Indonesian researchers, and work with them to analyze the data. Indonesian researchers will consent the participants, obtain stool and blood specimens, perform laboratory tests on the specimens, and enter data on participants and lab results.


Recruitment information / eligibility

Status Completed
Enrollment 17108
Est. completion date December 2015
Est. primary completion date March 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria: - Areas should be endemic for filariasis and have limited or no prior experience with MDA. Males and Females greater than or equal to 5 years of age. Exclusion Criteria: - Children less than 5 years of age.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Albendazole (annual)
Albendazole 400 mg pnce annually
Diethylcarbamazine (annual)
Diethylcarbamazine 6 mg/kg once annually
Albendazole (semiannual)
Albendazole 400 mg twice annually
Diethylcarbamazine (semiannual)
Diethylcarbamazine 6 mg/kg twice annually

Locations

Country Name City State
Indonesia University of Indonesia, Department of Parasitology Jakarta Java

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood Microfilariae (filarial parasites) will be detected in blood smears by microscopy. Samples will be collected in annual and semiannual community surveys. Prevalence rates (a measure of the disease rates in the population sampled) are expressed as % positive for microfilaremia (having microfilaria in the blood). 3 years
Secondary Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests This outcome is reported as the frequency of participants with positive Brugia Rapid antifilarial antibody tests. Data was only collected at baseline and at year 3 for this outcome measure and no antibody data was collected for the Pekalongan study sites. 3 years
Secondary Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test Prevalence of filarial antigenemia (detected with the Binax Filariasis Now card test "ICT" card test) among the population surveyed. Prevalence data are expressed as %. 3 years
Secondary Prevalence of Ascaris Infection Prevalence of Ascaris infection is defined by the number of participants with any Ascaris worm eggs present in their stool sample as analyzed with microscopy. 2 Years
Secondary Prevalence of Hookworm Infection Prevalence of hookworm infection is defined by the number of participants with any hookworm eggs present in their stool sample as analyzed with microscopy. 2 years
Secondary Prevalence of Trichuris Infection Prevalence of trichuris infection is defined by the number of participants with any trichuris worm eggs present in their stool sample as analyzed with microscopy. 2 years
See also
  Status Clinical Trial Phase
Completed NCT00375583 - Effect of Albendazole Dose on Clearance of Filarial Worms Phase 2
Completed NCT03664063 - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT01975441 - Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Phase 2
Completed NCT01629771 - Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India N/A
Completed NCT02784743 - Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Phase 4
Completed NCT03036059 - Twice Yearly Treatment for the Control of LF Phase 4
Completed NCT01905436 - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed NCT02509481 - Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Phase 2/Phase 3
Completed NCT03268252 - Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Completed NCT02927496 - A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Phase 3
Completed NCT02899936 - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis N/A
Completed NCT00511004 - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Phase 2
Active, not recruiting NCT04258670 - Spontaneous Antigenemia in Loiasis
Completed NCT02974049 - Lymphatic Filariasis (LF) in Ivory Coast N/A
Terminated NCT01213576 - Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi N/A
Completed NCT02929121 - A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Phase 3
Completed NCT00339417 - Effect of Albendazole Dose on Clearance of Filarial Worms Phase 2
Withdrawn NCT01903057 - Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Phase 4
Completed NCT02032043 - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)